Back to Search
Start Over
Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
- Source :
- Journal of Zhejiang University. Science. B
- Publication Year :
- 2020
- Publisher :
- Zhejiang University Press, 2020.
-
Abstract
- Background Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development. Methods Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-α2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors. Results A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%, P=0.006), dyspnea (8.8% vs. 25.0%, P=0.025), or diarrhea (4.4% vs. 19.4%, P=0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d, P=0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%, P=0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%, P=0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%, P=0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%, P=0.027) was higher and the hospitalization time (16 vs. 21 d, P=0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d, P=0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d, P=0.206). Conclusions IFN-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
Gastroenterology
law.invention
0302 clinical medicine
law
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)
Medicine
General Pharmacology, Toxicology and Pharmaceutics
Inhalation
Articles
Interferon (IFN)
General Medicine
倾向性评分
Intensive care unit
Virus Shedding
Hospitalization
Diarrhea
C-Reactive Protein
030220 oncology & carcinogenesis
medicine.symptom
Coronavirus Infections
Propensity score match
China
medicine.medical_specialty
Pneumonia, Viral
Interferon alpha-2
Antiviral Agents
General Biochemistry, Genetics and Molecular Biology
Betacoronavirus
03 medical and health sciences
Albumins
Internal medicine
Humans
Viral shedding
Propensity Score
R184
Glucocorticoids
Pandemics
Retrospective Studies
General Veterinary
SARS-CoV-2
business.industry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Sodium
Case-control study
COVID-19
Retrospective cohort study
Nasal Sprays
干扰素
COVID-19 Drug Treatment
Coronavirus disease 2019 (COVID-19)
匹配
030104 developmental biology
Nasal spray
Case-Control Studies
Propensity score matching
business
2019 冠状病毒病 (COVID-19)
Subjects
Details
- ISSN :
- 18621783 and 16731581
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Journal of Zhejiang University-SCIENCE B
- Accession number :
- edsair.doi.dedup.....2a23c983e9777717910930fe40794af2